Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Every mother transmits a secondgenetic legacy to her children and her children’s children, via mitochondrial DNA. Locked within it may be the key to destructive disease or a chance to alter future generations.
New genetic research has revealed the existence of certain regions in the human genome that have changed or mutated more rapidly than most others, resulting in differences that make us human among our primate cousins.
This week at a conference hosted by the journals Cell and The Lancet, Gladstone's Warner C. Greene discussed studies that for the first time mechanistically link the two pathogenic signatures of HIV infection: CD4 T cell depletion and chronic inflammation.
Chronicle columnist Leah Garchik comments on Dagmar Dolby's presentation of the 2013 Pacesetter Award to Gladstone's Lennart Mucke—for his lifelong dedication to overcoming Alzheimer’s disease—at last week's ARCS Scholar Luncheon.
Gladstone's Lennart Mucke and Keith Vossel are featured in an article about the growing body of research into the connection between Alzheimer’s disease and epilepsy—research that is providing hope for the 5 million patients currently suffering from the disease.
Gladstone's Warner C. Greene joins with other HIV/AIDS experts to discuss the possibility of curing HIV/AIDS, in a videotape of an October event in San Francisco.
Gladstone's Warner C. Greene comments on new research from Johns Hopkins University, which suggestst that the search-and-destroy mission against HIV just got much more complicated.
Do your genes inexorably write your destiny with respect to your fitness and health? The answers—in an article penned by Gladstone President R. Sanders "Sandy" Williams, MD, in the new online news site launched by Carlos Watson—may surprise you.
Once Gladstone negotiates the right to use a drug sitting on a biotech company's shelf, a clinical trial could be up and running within six to 12 months.
Experts—including Gladstone's Warner C. Greene—discussed the latest news on HIV cure research at a well-attended town hall forum in San Francisco on October 1.